Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. mp-101

MP-101

a novel drug for prevention and treatment peripheral neuropathy symptoms

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 MP-101 project word cloud

Explore the words cloud of the MP-101 project. It provides you a very rough idea of what is the project "MP-101" about.

diagnosed    suffering    none    eurotransmitter    oncology    neuropathic    unpleasant    troublesome    lowering    strength    treatment    stop    big    worldwide    approval    scaling    neuropathy    immuno    there    innovation    trials    world    sales    clinical    18m    supply    alone    normal    preventing    drafted    substantial    impeding    regulatory    nerve    chain    acts    mp    peripheral    drugs    endings    nerves    excitation    prevention    chemotherapy    lasting    prolonged    performing    central    20181    nervous    pharmaceuticals    metys    regardless    quality    therapies    glutamate    market    sensitization    gain    patients    modulator    signaling    treat    symptoms    difficult    risks    prematurely    life    brain    40    group    plan    painful    leads    spine    dependent    6m    7m    painkiller    sensory    cancer    101    fact    moderately    50x    diminishing    submitting    causing    excessive    agents    cipn    stimulation    damage    strategy    estimate    sedating    people    patient    chemotherapeutic    combination    2m    constant    pain   

Project "MP-101" data sheet

The following table provides information about the project.

Coordinator		 METYS PHARMACEUTICALS AG 

Organization address
address: GERBERGASSE 30
city: BASEL
postcode: 4001
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Project website https://metys-pharma.ch/en/about
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METYS PHARMACEUTICALS AG CH (BASEL) coordinator 50˙000.00

Map

 Project objective

There will be over 18m new cases of cancer worldwide in 20181, out of which about 3,7m in Europe alone. Studies estimate that up to 40% of all cancer patients develop chemotherapy-induced peripheral sensory neuropathy (CIPN), meaning over 1,6m patients in EU and 7,2m world-wide may experience CIPN each year. This group is only growing in number, due to the constant growth in new cases of diagnosed cancer. The new immuno-oncology drugs are increasingly being used in combination with chemotherapy. CIPN is a condition that affects the peripheral nervous system, leading to long-lasting, painful, and difficult-to-treat symptoms in the central nervous system, lowering the patient’s life quality and impeding patient’s normal activities. In fact, the CIPN induced pain is so strong and troublesome that many patients stop their cancer chemotherapy treatment prematurely. Regardless of the big and increasing number of people suffering from CIPN, only moderately effective therapies are available for the treatment, none specifically developed for CIPN, with substantial risks and unpleasant side effects for patients. Metys Pharmaceuticals is developing MP-101 - a novel, non-sedating, painkiller for prevention and for treatment of CIPN-associated neuropathic pain. Chemotherapeutic agents damage peripheral nerve endings, causing excessive signaling and sensitization which involves the eurotransmitter glutamate: this leads to prolonged excitation of the central nerves of the spine and brain. MP-101 acts as glutamate modulator, diminishing the strength of glutamate stimulation, or, if given early enough, preventing glutamate-dependent sensitization. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. The innovation project will focus on scaling up the production by 50x, performing phase 2 clinical trials, before submitting results to gain regulatory approval for sales across Europe.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MP-101" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MP-101" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More